At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Pre-Mkt 05-21 06:13:52 EDT
1.29
+0.06
+4.88%
High1.30Low1.24Vol455.63K
Open1.27D1 Closing1.23Amplitude4.87%
Mkt Cap78.27MTradable Cap71.75MTotal Shares60.67M
T/O580.21KT/O Rate0.82%Tradable Shares55.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MAIA Biotechnology Ends ATM Stock Offering Agreement
TIPRANKS  ·  05-15
MAIA Biotechnology Ends ATM Stock Offering Agreement
Maia Biotechnology Inc - Sold 3.1 Mln Shares for Gross Proceeds of $5.7 Mln Under Sales Agreement - SEC Filing
THOMSON REUTERS  ·  05-15
Maia Biotechnology Inc - Sold 3.1 Mln Shares for Gross Proceeds of $5.7 Mln Under Sales Agreement - SEC Filing
Maia Biotechnology Inc - to Terminate at the Market Offering Agreement Effective May 23, 2026 - SEC Filing
THOMSON REUTERS  ·  05-15
Maia Biotechnology Inc - to Terminate at the Market Offering Agreement Effective May 23, 2026 - SEC Filing
MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate
Benzinga  ·  05-11
MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate
Maia Biotechnology Q1 net loss widens 41% to $6.37 million
Reuters  ·  05-11
Maia Biotechnology Q1 net loss widens 41% to $6.37 million
Maia Biotech opens first US site for Phase 2 THIO-101 lung cancer trial
Reuters  ·  04-16
Maia Biotech opens first US site for Phase 2 THIO-101 lung cancer trial
MAIA Biotechnology secures funding for clinical trial of ateganosine
TIPRANKS  ·  04-08
MAIA Biotechnology secures funding for clinical trial of ateganosine
Maia Biotechnology says $33 million stock offering fully funds Phase 3 NSCLC trial
Reuters  ·  04-08
Maia Biotechnology says $33 million stock offering fully funds Phase 3 NSCLC trial
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
GlobeNewswire  ·  04-08
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
Maia Biotechnology announces annual shareholder meeting in virtual format
Reuters  ·  04-07
Maia Biotechnology announces annual shareholder meeting in virtual format
MAIA Biotechnology Awards Executive Bonuses After Successful Financing
TIPRANKS  ·  04-03
MAIA Biotechnology Awards Executive Bonuses After Successful Financing
Maia Biotechnology CEO receives one-time $0.3 million bonus tied to capital raise
Reuters  ·  04-03
Maia Biotechnology CEO receives one-time $0.3 million bonus tied to capital raise
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes
TIPRANKS  ·  04-01
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes
BRIEF-Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Reuters  ·  03-31
BRIEF-Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026
TIPRANKS  ·  03-27
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026
MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
Benzinga  ·  03-24
MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
Maia Biotechnology FY 2025 net loss was USD 22.4 million as R&D expenses rose 45% to USD 14.5 million
Reuters  ·  03-23
Maia Biotechnology FY 2025 net loss was USD 22.4 million as R&D expenses rose 45% to USD 14.5 million
MAIA Biotechnology Completes $30 Million Public Stock Offering
TIPRANKS  ·  03-05
MAIA Biotechnology Completes $30 Million Public Stock Offering
BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
Reuters  ·  03-05
BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing
THOMSON REUTERS  ·  03-05
Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--